切换至 "中华医学电子期刊资源库"

中华老年病研究电子杂志 ›› 2021, Vol. 08 ›› Issue (01) : 41 -44. doi: 10.3877/cma.j.issn.2095-8757.2021.01.010

所属专题: 文献

综述

胆汁酸与高血压的关系
卢丹1, 方宁远2, 汪海娅2,()   
  1. 1. 430060 武汉市第三医院全科医学科
    2. 200127 上海交通大学医学院附属仁济医院老年科
  • 收稿日期:2020-04-28 出版日期:2021-02-28
  • 通信作者: 汪海娅

The relationship between bile acid and hypertension

Dan Lu1, Ningyuan Fang2, Haiya Wang2,()   

  1. 1. Department of General Practice, Wuhan Third Hospital, Wuhan 430060, China
    2. Department of Geriatrics, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200127, China
  • Received:2020-04-28 Published:2021-02-28
  • Corresponding author: Haiya Wang
引用本文:

卢丹, 方宁远, 汪海娅. 胆汁酸与高血压的关系[J]. 中华老年病研究电子杂志, 2021, 08(01): 41-44.

Dan Lu, Ningyuan Fang, Haiya Wang. The relationship between bile acid and hypertension[J]. Chinese Journal of Geriatrics Research(Electronic Edition), 2021, 08(01): 41-44.

高血压是最常见的慢性病,也是心血管病最主要的危险因素。目前,关于原发性高血压的病因和发病机制尚未完全阐明,进一步深入探索其相关因素,对于心血管疾病的预防和治疗有着重大的临床意义。胆汁酸是核受体法尼醇X受体的内源性激动剂,同时也是11β羟化固醇脱氢酶的内源性抑制剂,可能参与了原发性高血压等心血管疾病的发生和进展。本文现对胆汁酸与高血压等心血管疾病的关系进行综述,以期为临床提供参考。

Hypertension is the most common chronic disease and the main risk factor of cardiovascular disease. At present, the etiology and pathogenesis of essential hypertension has not been fully elucidated. Further exploration of its related factors has great clinical significance for the prevention and treatment of cardiovascular disease. Bile acids are endogenous agonists of farnesol X receptor and endogenous inhibitors of 11 β - hydroxysteroid dehydrogenase, which may be involved in the occurrence and progress of cardiovascular diseases such as essential hypertension. This article reviews the relationship between bile acids and cardiovascular diseases such as hypertension, in order to provide reference for clinical practice.

[1]
Modica S, Gadaleta RM, Moschetta A. Deciphering the nuclear bile acid receptor FXR paradigm[J]. Nucl Recept Signal, 2010, 8:e005.
[2]
Funabashi M, Grove TL, Wang M, et al. A metabolic pathway for bile acid dehydroxylation by the gut microbiome[J]. Nature, 2020, 582(7813):566-570.
[3]
Marin JJ, Macias RI, Briz O, et al. Bile acids in physiology, pathology and pharmacology[J]. Curr Drug Metab, 2015, 17(1):4-29.
[4]
Perez MJ, Briz O. Bile-acid-induced cell injury and protection[J]. World J Gastroenterol, 2009, 15(14):1677-1689.
[5]
Fiorucci S, Distrutti E. Bile acid-activated receptors, intestinal microbiota, and the treatment of metabolic disorders[J]. Trends Molecul Med, 2015, 21(11):702-714.
[6]
Juřica J, Dovrtělová G, Nosková K, et al. Bile Acids, Nuclear Receptors and Cytochrome P450[J]. Physiol Res, 2016, 65(Suppl 4):S427-S440.
[7]
Chiang JYL. Bile acids: Regulation of synthesis[J]. J Lipid Res, 2009, 50(10):1955.
[8]
Parks DJ, Blanchard SG, Bledsoe RK, et al. Bile acids: Natural ligands for an orphan nuclear receptor[J]. Science, 1999, 284(5418):1365-1368.
[9]
Ma H, Patti ME. Bile acids, obesity, and the metabolic syndrome[J]. Best Pract Res Clin Gastroenterol, 2014, 28(4):573-583.
[10]
Ferrer SC, Ehret G, Pechèrebertschi A. [Screening and management of hypertension in elderly][J]. Rev Med Suisse, 2015, 11(485):1638, 1640-1644.
[11]
刘力生.中国高血压防治指南2010[J].中华心血管病杂志,2011,39(7):42-93.
[12]
Li Y, Yang L, Wang L, et al. Burden of hypertension in China: A nationally representative survey of 174,621 adults[J]. Int J Cardiol, 2017, 227:516-523.
[13]
陈义林.原发性高血压患者血清总胆汁酸和尿酸水平的变化[J].安徽医药,2007,11(7):622-623.
[14]
林青,许少锋.血浆总胆汁酸与原发性高血压的关系[J].福建医科大学学报,2001,35(2):171-173.
[15]
庄梅.血清总胆汁酸水平对原发性高血压致病作用的探讨[J].贵州医药,2002,26(6):498-499.
[16]
张永生,吴平生,刘伊丽.动态血压监测高血压病患者血压及其与血浆总胆汁酸水平的关系[J].中国现代医学杂志,1998,8(11):45.
[17]
张永生,吴平生.胆汁酸对血压影响的多面性及其可能机制[J].中国现代医学杂志, 2000,10(6):33-34.
[18]
李易,蔡大润,包有生,等.总胆汁酸在高血压病中的作用初探[J].临床荟萃,1999,14(7):292-292.
[19]
徐辰祺,卜军,何奔.胆汁酸在心血管疾病中的作用[J].生理科学进展,2015,46(6):424-428.
[20]
Friedrich LC. 11-βhydroxysteroid dehydrogenase-2 and salt-sensitive hypertension[J]. Circulation, 2016, doi:10.1161/CIRCULATIONAHA.116.022038.
[21]
Yau M, Haider S, Khattab A, et al. Clinical, genetic, and structural basis of apparent mineralocorticoid excess due to 11β-hydroxysteroid dehydrogenase type 2 deficiency[J]. Proc Natl Acad Sci USA, 2017, 114(52):E11248-E11256.
[22]
Morris DJ, Souness GW. Endogenous 11 beta-hydroxysteroid dehydrogenase inhibitors and their role in glucocorticoid Na+ retention and hypertension[J]. Endocr Res, 1996, 22(4):793-801.
[23]
Li C, Li J, Weng X, et al. Farnesoid X receptor agonist CDCA reduces blood pressure and regulates vascular tone in spontaneously hypertensive rats[J]. J Am Soc Hypertens, 2015, 9(7):507-516.
[24]
Mazancová K, Miksík I, Kunes J, et al. Sexual dimorphism of 11 beta-hydroxysteroid dehydrogenase in hypertensive and normotensive rats[J]. Hypertens Res, 2003, 26(4):333-338.
[25]
Kosicka K, Cymerys M, Majchrzak-Celińska A, et al. 11β-Hydroxysteroid dehydrogenase type 2 in hypertension: comparison of phenotype and genotype analysis[J]. J Hum Hypertens, 2013, 27(8):510-515.
[26]
Evans LC, Ivy JR, Wyrwoll C, et al. Conditional deletion of hsd11b2 in the brain causes salt appetite and hypertension[J]. Circulation, 2016, 133(14):1360-1370.
[27]
Al-Salami H, Mamo JC, Mooranian A, et al. Long-term supplementation of microencapsulated ursodeoxycholic acid prevents hypertension in a mouse model of insulin resistance[J]. Exp Clin Endocrinol Diabetes, 2016, 125(1):28-32.
[28]
Charach G, Argov O, Geiger K, et al. Diminished bile acids excretion is a risk factor for coronary artery disease: 20-year follow up and long-term outcome[J]. Therap Adv Gastroenterol, 2018, 11:1756283X1774342.
[29]
徐冬新,傅颖.冠状动脉粥样硬化性心脏病患者血清总胆汁酸、超敏C反应蛋白、同型半胱氨酸、血脂水平变化的相关性研究[J].中国卫生检验杂志,2016,26(17):2503-2505.
[30]
公言伟,李建国,王全义.冠心病患者血清总胆汁酸水平与冠状动脉病变严重程度的相关性研究[J].中西医结合心血管病电子杂志,2015,3(16):63-64.
[31]
闫静静,范慧倩,杨玲.胆汁酸与心律失常[J].中华肝脏病杂志,2020,28(4):361-364.
[32]
Vasavan T, Ferraro E, Ibrahim E, et al. Heart and bile acids-Clinical consequences of altered bile acid metabolism[J]. Biochim Biophys Acta Mol Basis Dis, 2018, 1864(4 Pt B):1345-1355.
[33]
Cck M, Ueland T, Broch K, et al. Increased secondary/primary bile acid-ratio in chronic heart failure[J]. J Cardiac Fail, 2017, 23(9):666-671.
[34]
单瑞,杨培根.老年慢性心衰患者血清胆汁酸水平与炎症因子及心室重构的关系[J].天津医药,2018,46(1):42-45.
[35]
Desai M, Mathur B, Eblimit Z, et al. Bile acid excess induces cardiomyopathy and metabolic dysfunctions in the heart[J]. Hepatology, 2017, 65(1):189-201.
[1] 靳茜雅, 黄晓松, 谭诚, 蒋琴, 侯昉, 李瑶悦, 徐冰, 贾红慧, 刘文英. 产前他克莫司治疗对先天性膈疝大鼠病理模型肺血管重构的影响[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(04): 428-436.
[2] 李琛, 张惟佳, 潘亚萍. 牙周炎与系统性疾病之间关系的应用思考:2022年EFP和WONCA欧洲分部联合研讨会共识报告的解读及启示[J]. 中华口腔医学研究杂志(电子版), 2023, 17(05): 322-327.
[3] 李建美, 邓静娟, 杨倩. 两种术式联合治疗肝癌合并肝硬化门静脉高压的安全性及随访评价[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 41-44.
[4] 王昆, 潘迪, 王庆, 江克华, 孙发. 机器人手术治疗膀胱副神经节瘤一例报告[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(03): 291-292.
[5] 张其坤, 商福超, 李琪, 栗光明, 王孟龙. 联合脾切除对肝癌合并门静脉高压症患者根治性切除术后的生存获益分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 613-618.
[6] 赫嵘, 贾哲, 张珂, 李代京, 张萌, 蒋力. 基于PSM分析腹腔镜肝切除联合Hassab术治疗合并门静脉高压症肝癌疗效[J]. 中华肝脏外科手术学电子杂志, 2023, 12(04): 376-383.
[7] 许语阳, 吕云福, 王葆春. 乙肝后肝硬化门静脉高压症脾肿大外科治疗进展[J]. 中华肝脏外科手术学电子杂志, 2023, 12(04): 469-473.
[8] 运陌, 李茂芳, 王浩, 刘东远. 微创穿刺引流联合吡拉西坦、乌拉地尔治疗基底节区高血压性脑出血的临床研究[J]. 中华脑科疾病与康复杂志(电子版), 2023, 13(05): 278-285.
[9] 刘政委, 仪立志, 尹夕龙, 孔文龙, 纠智松, 张文源. 锥颅血肿外引流与神经内镜手术治疗老年基底节区高血压性脑出血的疗效分析[J]. 中华脑科疾病与康复杂志(电子版), 2023, 13(05): 299-303.
[10] 许秀兰, 朱建建. 血压变异性与伴H型高血压的急性脑梗死患者预后不良的临床关系分析[J]. 中华脑科疾病与康复杂志(电子版), 2023, 13(04): 199-204.
[11] 刘锦秀, 王晓伟, 张同乐, 姜爱华. 青年社会体检者、医务工作者及心肌梗死患者心血管疾病高危因素的对比研究[J]. 中华临床医师杂志(电子版), 2023, 17(03): 249-254.
[12] 吴晓翔, 杨波, 李景漩, 张凤玲, 郭桂辉, 郑少培. 脐动脉超声检查联合NLR、sFlt-1/PLGF对妊娠高血压综合征患者不良妊娠结局的预测价值[J]. 中华临床医师杂志(电子版), 2023, 17(03): 266-271.
[13] 万基伟, 耿乐乐, 龚雪梅, 邓伟滨. 混元灸治疗阳虚型高血压伴颈动脉粥样硬化患者的临床研究[J]. 中华针灸电子杂志, 2023, 12(03): 101-105.
[14] 杜青瑶, 曹颖雯, 林健雄, 郝润, 王静敏, 徐锐权, 寇晓霞. 肠道菌群促进诺如病毒感染的机制[J]. 中华临床实验室管理电子杂志, 2023, 11(04): 241-244,255.
[15] 罗峥, 张蔚, 徐晓云, 史楠, 张燕, 赵梅珍, 刘康永, 赵玫, 李小攀. 65岁以上心脑血管疾病共存病例诊治分析[J]. 中华脑血管病杂志(电子版), 2023, 17(03): 207-213.
阅读次数
全文


摘要